Mission Therapeutics
2 known investors
Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis. It operates in the biotech and drug discovery field focused on DUB biology.